Raising a Series A in medtech.
A medtech Series A usually funds the clinical study and the regulatory filing. Here is the bar and who usually leads.
Medtech
Medtech investors fund a device through three gates: a regulatory pathway, clinical evidence and a way to get paid. Your FDA route sets how much capital you need and how long it takes.
What Series A investors expect in medtech
Diligence gets clinical and regulatory. Expect experts to test each of these.
A clear regulatory plan
- Agreement with the FDA on testing, if you sought it
- A filing timeline with named owners
- Quality system and design controls in place
A clinical study that answers it
- First-in-human or feasibility data, if your path needs it
- A pivotal study design with endpoints that matter
- Sites, investigators and a realistic enrollment plan
Market access mapped
- Coverage and payment plan for the procedure
- Hospital value analysis committees you will face
- Key physicians ready to use and speak for it
How the round comes together
Medtech Series A rounds are usually led by specialist health or device funds.
- 1 · A specialist fund leads
- 2 · Existing investors keep their share
- 3 · Strategics join
Multi-stage VCs
Often leads
Venture funds with device teams lead most medtech Series A rounds.
Corporate VCs
Sometimes
Device makers invest to gain early access to a possible acquisition.
Pre-seed & seed funds
Often follows
Seed investors usually take their pro-rata.
Family offices
Sometimes
Families with health care roots co-invest beside the lead.
A priced round with a board
Series A is priced equity. Expect board seats, standard protections and sometimes tranches tied to study enrollment or a filing. If a device maker invests, check any right of first refusal on a sale.
The slides investors read first
Device
Final design and what it changes for patients.
Regulatory
Pathway, FDA feedback and filing date.
Clinical study
Design, endpoints, sites and timing.
Market access
Codes, coverage and hospital buyers.
The plan
Cash to clearance and the first sales.
Questions founders ask
How does my FDA pathway change the round?
Paths that compare you to an existing device usually need less clinical data and less money. Novel devices on a De Novo or PMA route need more evidence, more time and larger rounds.
Will a device maker's venture arm want to acquire us?
It may hope to. That can help at exit, but terms that give one buyer special rights can lower what others will pay. Have your lawyer review them.
Sources
Sources: FDA guidance on device classification, 510(k), De Novo and PMA pathways; CMS coverage and coding resources; investors' published criteria. Editorial content, reviewed quarterly. Not financial, legal or medical advice.
Other stages
Related sectors
Who funds this round
Learn the terms
Run the numbers
Raise in your city
Inside Unicorn Factory
Free account
Investor matching is coming to your free account. Create it now and we will match your round the day it opens. Until then, get an honest read on your deck.